Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > Tidbits from today's presentation

<< Previous

Bullboard Posts

Next >>

Comment by Hankerchiefon Dec 17, 2020 3:48pm

222 Views

Post# 32130472

RE:RE:RE:Tidbits from today's presentation

Sounds good. Thanks!

tdon1229 wrote:

Hankerchief wrote: Thanks for the info....
Wonder why there has to be a wait until Q3 2021 to start phase 1 work on GBM/NSCLC?
Would think they could hop on this now?

Eoganacht wrote: 3Q2021 - Commence Phase 1b clinical studies for GBM and NSCLC

4Q2021 - Enrol and treat 10 GBM and 10 NSCLC patients Canada

2021 - Breakthrough Designation from FDA for results of first 20 - 25 patients

Theralase has no affiliation with the study being conducted by Roswell Park and Dr. McFarland

FDA requirement for CR at 360 days is 360 days post the initial CR, not 360 days post the initial treatment. This has been done at the FDA's request and has lengthened the duration of the phase 2 study. Competing treatments such as Merck's Keytruda measured 360 day CR from the initial treatment which gives their results an advantage over Theralase as it represents a shorter duration.

No money now for another trial ... need to show some results in 1H2021, raise the SP and raise some cash in order to proceed in 3Q2021 ... salaries and overhead during the COVID shutdown apparently used up what they had set aside for additional trials, so those trials have been delayed ... options include grant money and also partnership/joint venture, but they're not in place yet.